Last reviewed · How we verify
Kleb4V target dose — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Kleb4V target dose (Kleb4V target dose) — LimmaTech Biologics AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Kleb4V target dose TARGET | Kleb4V target dose | LimmaTech Biologics AG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Kleb4V target dose CI watch — RSS
- Kleb4V target dose CI watch — Atom
- Kleb4V target dose CI watch — JSON
- Kleb4V target dose alone — RSS
Cite this brief
Drug Landscape (2026). Kleb4V target dose — Competitive Intelligence Brief. https://druglandscape.com/ci/kleb4v-target-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab